Share this article
Biologics Biosimilars Bookletfinal Pdf

Biologics and Biosimilars

AARDA Releases White Paper to Educate Patients.

Leading Autoimmune Patient Advocacy Group Survey Finds Overwhelming Majority of Patients Lack Understanding of Biosimilar Drugs.

“Unlike chemically based drugs, biologic medicines have the unique ability to target the underlying cause of a disease, representing a huge breakthrough for patients suffering from many serious autoimmune diseases,” said Virginia Ladd, President and Executive Director of AARDA. “The results of our member survey illuminated just how limited awareness is around these life-saving medications – especially among those who need them most.”

The white paper provides a comprehensive overview of biologic medicines, which are used to treat serious illnesses including autoimmune diseases, immune deficiencies and cancer, and comes as the U.S. Food and Drug Administration (FDA) works to finalize its guidelines for the approval of biosimilars – drugs that are similar but not identical to original biologic medicines.

The survey of 362 Autoimmune Association members – 96 percent of whom reported living with an autoimmune disease – found that more than 80 percent of respondents did not know what biosimilar medicines were and about 52 percent did not understand how biologics differ from chemical drugs.

 
In order to increase awareness among its member community, AARDA’s white paper offers insight into:

  • biologic medicines, which are made from complex molecules of living material rather than chemical compounds, and the significance of these therapies for patients with
    severe medical conditions,
  • how biologic medicines effectively treat patients with a number of autoimmune diseases,
  • why biosimilar drugs are not “generic” versions of biologics,
  • what are the safety concerns for patients when switching between biologic and biosimilar
    products,
  • what are the policy issues surrounding the approval of biosimilar medicines in the U.S.

[button title=”Read the White Paper on Biologics and Biosimilars” icon=”” icon_position=”” link=”https://autoimmune.org/wp-content/uploads/2017/04/BiosimilarsWhitePaperPressRelease-pdf.jpg” target=”_blank” color=”blue” font_color=”” size=”2″ full_width=”” class=”” download=”” onclick=””]

 

Share this article

Join our email list

Receive the latest blog articles, news, and more right to your inbox!

  • Categories

  • Archives

Related articles you might be interested in

Autoimmune Association Image Do Not Touch

Autoimmune Association Advocates for Federal Legislation to Reform Harmful PBM Practices

What are Pharmacy Benefit Managers (PBMs)? Pharmacy Benefit Managers, or PBMs, are entities that handle prescription drug benefits for health insurance plans. They...
Autoimmune Association Image Do Not Touch

5 Promising Areas in Autoimmune Research

In a recent discussion at the Autoimmune Community Summit, Nina Luning Prak, MD, PhD, chair of the Autoimmune Association’s Medical and Scientific Advisory...
Autoimmune Association Image Do Not Touch

Raising Hope: Andy Capmany

Welcome to our inspiring blog series, Raising Hope, where we feature stories of individuals who are making a difference for the autoimmune community...
Autoimmune Association Image Do Not Touch

Erika Page: Finding Purpose in Connection and Community

Erika Page is a fun-loving, compassionate mom of two. She also lives with vitiligo. And although she struggled significantly with the changes in...

Find more resources on autoimmunity

Learn more about autoimmunity, diagnosis tips, how to find a physician, and more.